cinacalcet teva 30 mg
teva israel ltd - cinacalcet as hydrochloride - tablets - cinacalcet as hydrochloride 30 mg - cinacalcet - treatment of secondary hyperparathyrodism (hpt) in patients with end-dtage renal disease (esrd) on maintenance dialysis therapy. cinacalcet teva may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols, as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma.reduction of hypercalcaemia in patients with:• parathyroid carcinoma.• primary hpt for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.
cinacalcet teva 60 mg
teva israel ltd - cinacalcet as hydrochloride - tablets - cinacalcet as hydrochloride 60 mg - cinacalcet - treatment of secondary hyperparathyrodism (hpt) in patients with end-dtage renal disease (esrd) on maintenance dialysis therapy. cinacalcet teva may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols, as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma.reduction of hypercalcaemia in patients with:• parathyroid carcinoma.• primary hpt for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.
cinacalcet teva 90 mg
teva israel ltd - cinacalcet as hydrochloride - tablets - cinacalcet as hydrochloride 90 mg - cinacalcet - treatment of secondary hyperparathyrodism (hpt) in patients with end-dtage renal disease (esrd) on maintenance dialysis therapy. cinacalcet teva may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols, as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma.reduction of hypercalcaemia in patients with:• parathyroid carcinoma.• primary hpt for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.
cinacalcet pharmsol 30mg film-coated tablets
pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - cinacalcet hydrochloride - film-coated tablet - cinacalcet hydrochloride 30 mg - calcium homeostasis
cinacalcet pharmsol 60mg film-coated tablets
pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - cinacalcet hydrochloride - film-coated tablet - cinacalcet hydrochloride 60 mg - calcium homeostasis
cinacalcet pharmsol 90 mg film-coated tablets
pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - cinacalcet hydrochloride - film-coated tablet - cinacalcet hydrochloride 90 mg - calcium homeostasis
cinacalcet tablet
cipla usa inc. - cinacalcet hydrochloride (unii: 1k860wsg25) (cinacalcet - unii:uaz6v7728s) - cinacalcet 30 mg - cinacalcet hydrochloride tablets are indicated for the treatment of secondary hyperparathyroidism (hpt) in adult patients with chronic kidney disease (ckd) on dialysis [see clinical studies (14.1)]. limitations of use: cinacalcet hydrochloride tablets are not indicated for use in patients with ckd who are not on dialysis because of an increased risk of hypocalcemia [see warnings and precautions (5.1)]. cinacalcet tablets are indicated for the treatment of hypercalcemia in adult patients with parathyroid carcinoma [see clinical studies (14.2)] . cinacalcet hydrochloride tablets are indicated for the treatment of hypercalcemia in adult patients with primary hpt for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy. [see clinical studies (14.3)] . cinacalcet hydrochloride tablets treatment initiation is contraindicated if serum calcium is less than the lower limit of the normal range [see warnings and precautions (5.1)]. risk summary l
pms-cinacalcet tablet
pharmascience inc - cinacalcet (cinacalcet hydrochloride) - tablet - 30mg - cinacalcet (cinacalcet hydrochloride) 30mg - other miscellaneous therapeutic agents
pms-cinacalcet tablet
pharmascience inc - cinacalcet (cinacalcet hydrochloride) - tablet - 60mg - cinacalcet (cinacalcet hydrochloride) 60mg - other miscellaneous therapeutic agents
pms-cinacalcet tablet
pharmascience inc - cinacalcet (cinacalcet hydrochloride) - tablet - 90mg - cinacalcet (cinacalcet hydrochloride) 90mg - other miscellaneous therapeutic agents